Clinical Trial Update: A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) [Phase 1]

View source ↗

Summary

Phase 1 trial of a Notch signaling pathway inhibitor (MK-0752) in T-cell acute lymphoblastic leukemia/lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Myelodysplastic Syndromes
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• MK-0752

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia | Phase 1 | Status: TERMINATED